Drugs / Pegylated liposomal doxorubicin
Trials 0
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT03690739 Comparator | Aug 2019 → Mar 2021 | ovarian carcinoma | AGO Research GmbH | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pegylated liposomal doxorubicin | “Pegylated liposomal doxorubicin 30 mg/m² + Trabectedin 1.1 mg/m² (q3w)” NCT03690739 ↗ |
| Known as | PLD | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03690739 ↗ |